Announcements Trials
Browse Landscape

Phase

Phase NA 76Phase 2 14Phase 4 4Phase 3 4Phase EARLY_PHASE1 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 1128Carcinoma, Non-Small-Cell Lung 718Neoplasms 545Prostatic Neoplasms 502Colorectal Neoplasms 438Multiple Myeloma 336Lung Neoplasms 309Neoplasm Metastasis 288Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 245Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 171Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 161Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

Tamoxifen 2pegfilgrastim 1exemestane 1abemaciclib 1Tretinoin 1Tocopherols 1Standard of Care 1Mifepristone 1Letrozole 1Isotretinoin 1Dexmedetomidine 1Cannabidiol 1Bupivacaine 1Anastrozole 1Alitretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Breast Cancer Female × Clear all
NCT03063073 2026-02-12

pec's

South Egypt Cancer Institute

Phase 3 Completed
60 enrolled
Breast

Breast Cancer Female

NCT04584853 2026-01-14

POETIC-A

Institute of Cancer Research, United Kingdom

Phase 3 Active not recruiting
123 enrolled
Breast

Breast Cancer Female

NCT05016349 2021-08-23

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Kafrelsheikh University

Phase 3 Unknown
160 enrolled
Breast

Breast Cancer Female

NCT03381417 2018-01-02

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 3 Completed
128 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡